- Early-stage unfavorable cHL; Peter Borchmann
- KEYNOTE 204; Pier Luigi Zinzani
- Hodgkin’s Lymphoma in the era of targeted therapy; Peter Johnson
Visit
Day One
Day one of the meeting featured sessions on Hodgkin’s lymphoma, immunotherapy and the microenvironment as well as novel ADCs and CD20/ CD3 bispecific antibodies.
Session I: Hodgkin’s Lymphoma
Session II: Immunotherapy/ Microenvironment
- Crosstalk between lymphocytes and their microenvironment; Jan A. Burger
- CBT in specific lymphoma subtypes; Stephen Ansell
Session III: Novel Therapies Part I
- Novel ADCs; Laurie Sehn
- CD20 / CD3 bispecific antibodies: How to choose?; Martin Hutchings
- Oral PI3K delta (δ) inhibitors in lymphoma; Jennifer Brown
Day Two
Day two of the meeting featured sessions on choosing a novel BTK inhibitor, SINE inhibitors in DLBCL and T-cell therapies for lymphoma.
Session IV: Novel Therapies Part II
- Novel BTK inhibitors: how to choose?; Tom Witzig
- SINE inhibitors: Selinexor; John Kuruvilla
- Tafasitamab (MOR208) in DLBCL; Gilles Salles
Session V: T-cell Therapies for Lymphoma
- CD19-CAR-T cells; Jeremy Abramson
- CD30, CD5 and/or 7 CAR-T cells; Cath Bollard
- T cell-engaging therapies – BiTEs and beyond; Stephen Gottschalk
Check out our latest Lymphoma content!
Our Lymphoma Channel examines the latest updates across lymphoma subtypes.
With content featuring expert interviews from major international congresses and news by subtype, this is one for your bookmarks!
To keep updated on all the latest in lymphoma and beyond, subscribe to our newsletter here.
VJHemOnc is intended for Healthcare Professionals onlyBy choosing to continue, you are confirming that you are a healthcare professional
Sign-up for our Newsletter!
Keep up to date with all the latest news with our monthly newsletter
The content of VJHemOnc is intended for healthcare professionals